214 12-Month Post Marketing Safety Surveillance Data of Chewable Inulin Fiber
نویسندگان
چکیده
منابع مشابه
Social Media Listening for Routine Post-Marketing Safety Surveillance.
INTRODUCTION Post-marketing safety surveillance primarily relies on data from spontaneous adverse event reports, medical literature, and observational databases. Limitations of these data sources include potential under-reporting, lack of geographic diversity, and time lag between event occurrence and discovery. There is growing interest in exploring the use of social media ('social listening')...
متن کاملPost-marketing surveillance of buprenorphine.
PURPOSE This study was undertaken to evaluate the adverse consequences of recently introduced higher strength (0.4 and 2.0 mg per tablet) buprenorphine in Indian market. Buprenorphine, a partial opiate agonist and antagonist, is an emerging alternative to methadone as an agent for long-term treatment of opiate dependence. METHODS The current investigation was conducted through a multi-centric...
متن کاملEvaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...
متن کاملPostmarketing surveillance of the safety of cimetidine: 12 month mortality report.
A total of 9928 patients taking cimetidine and 9351 controls were recruited to a postmarketing drug surveillance study in Glasgow, Nottingham, Oxford, and Portsmouth. Takers were identified by the Prescription Pricing Bureau at Nottingham and by dispensing pharmacists at the other three centres. All but 1.2% of the takers and 1.6% of the controls were successfully followed up for one year durin...
متن کاملSafety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
INTRODUCTION Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and data in patients with MS from Japan were limited, we conducted an all-case post-marketing surveillan...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Gastroenterology
سال: 2019
ISSN: 0002-9270,1572-0241
DOI: 10.14309/01.ajg.0000590388.63444.9a